Dulaglutide
Generic name
Dulaglutide
Brand name
ATC Code
A10BJ05
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
The AUC in children (10-18 years, n=128) was approximately 37% lower than that in adult patients. This difference was not considered clinically relevant. [SmPC]
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Type 2 diabetes mellitus |
|---|
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
The safety profile in children is similar to that of adult patients.
The immunogenicity profile in children is similar to adult patients. 2.1% and 4.0% of patients treated with placebo and dulaglutide, respectively, in the pediatric study developed antibodies against dulaglutide during treatment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Biguanides | ||
|---|---|---|
| A10BA02 | ||
| Sulfonylureas | ||
|---|---|---|
| A10BB01 | ||
| Combinations of oral blood glucose lowering drugs | ||
|---|---|---|
| A10BD20 | ||
| Glucagon-like peptide-1 (GLP-1) analogues | ||
|---|---|---|
| A10BJ01 | ||
| A10BJ02 | ||
| Sodium-glucose co-transporter 2 (SGLT2) inhibitors | ||
|---|---|---|
| A10BK01 | ||
| A10BK03 | ||
Reference
- Eli Lilly Nederland B.V., SmPC Trulicity (EU/1/14/956/001) Rev 17,16-3-2023, www.ema.europa.eu
Changes
Therapeutic Drug Monitoring
Overdose
